S2Medical AB (S2M) - Cash Flow Conversion Efficiency
Based on the latest financial reports, S2Medical AB (S2M) has a cash flow conversion efficiency ratio of 0.068x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr1.29 Million ≈ $138.82K USD) by net assets (Skr18.88 Million ≈ $2.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
S2Medical AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how S2Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read S2Medical AB (S2M) financial obligations for a breakdown of total debt and financial obligations.
S2Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of S2Medical AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Panthera Resources PLC
LSE:PAT
|
-0.312x |
|
Gyldendal A/S
CO:GYLD-B
|
0.262x |
|
Oxbridge Re Holdings Equity Warrant
NASDAQ:OXBRW
|
0.067x |
|
Ivory Properties Group Bhd
KLSE:5175
|
0.629x |
|
EPE Special Opportunities Limited
LSE:ESO
|
-0.015x |
|
Cora Gold Limited
LSE:CORA
|
-0.013x |
|
Panther Securities P L C
LSE:PNS
|
0.016x |
|
Ortel Communications Limited
NSE:ORTEL
|
-0.035x |
Annual Cash Flow Conversion Efficiency for S2Medical AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of S2Medical AB from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see S2M market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr9.88 Million ≈ $1.06 Million |
Skr675.00K ≈ $72.64K |
0.068x | -83.97% |
| 2024-12-31 | Skr11.80 Million ≈ $1.27 Million |
Skr5.03 Million ≈ $541.40K |
0.426x | +104.28% |
| 2023-12-31 | Skr1.66 Million ≈ $178.42K |
Skr-16.52 Million ≈ $-1.78 Million |
-9.964x | -150.39% |
| 2022-12-31 | Skr7.07 Million ≈ $760.76K |
Skr-28.13 Million ≈ $-3.03 Million |
-3.979x | -197.08% |
| 2021-12-31 | Skr14.68 Million ≈ $1.58 Million |
Skr-19.67 Million ≈ $-2.12 Million |
-1.339x | -244.25% |
| 2020-12-31 | Skr32.77 Million ≈ $3.53 Million |
Skr-12.75 Million ≈ $-1.37 Million |
-0.389x | +42.87% |
| 2019-12-31 | Skr25.11 Million ≈ $2.70 Million |
Skr-17.10 Million ≈ $-1.84 Million |
-0.681x | -132.57% |
| 2018-12-31 | Skr43.55 Million ≈ $4.69 Million |
Skr-12.75 Million ≈ $-1.37 Million |
-0.293x | +63.05% |
| 2017-12-31 | Skr7.38 Million ≈ $793.67K |
Skr-5.85 Million ≈ $-629.12K |
-0.793x | +28.05% |
| 2016-12-31 | Skr2.75 Million ≈ $296.05K |
Skr-3.03 Million ≈ $-326.18K |
-1.102x | -- |
About S2Medical AB
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and… Read more